Spots Global Cancer Trial Database for Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Official Title: Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Study ID: NCT01226472
Interventions
Study Description
Brief Summary: This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in study, KW-0761-001.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University, Stanford, California, United States
Contact Details
Name: Michael Kurman, M.D.
Affiliation: Kyowa Hakko Kirin Pharma, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
